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Abstract 
UDP-glucuronosyltransferases (UGTs), which are one of the important detoxifying 
enzymes, catalyze the glucuronidation of a wide range of endobiotic and xenobiotic 
compounds. The glucuronidation can lead to the clearance of drugs and xenobiotics. 
The induction of UGTs is believed to enhance elimination of metabolites. This study 
was to investigate the induction of UGT1A8 in the rat liver, and to study the substrate 
specificity of this newly identified UGT1A8. Study of the biochemical properties and 
the substrate specificity of UGT1A8 would allow us to understand the functions of the 
enzyme. 
The expression and the properties of UGT1A8 were studied. Rat liver cells (clone 9 
and H4IIE) and rats (Wistar and j/j rats) were treated with licorice and 18 ^ 
glycyrrhetinic acid to study the expression of the liver UGT1A8. It was found that the 
gene could be induced by both treatments. The liver UGT1A8 cDNA was obtained 
from the rat liver and the gene was cloned and expressed in E. coli system. The gene 
encoded for a protein with 531 a.a. with a molecular weight of 55kDa. The purified 
protein was assayed with different substrates: bilirubin, couramin, 1-naphthol, 
4-nitrophenol and phenol red. The results showed that UGT1A8 can be expressed in E. 
coli JM109 and the protein can be purified with centrifligation and Ni+-column. The 
enzyme showed activity towards couramin and l-naphthol. The present findings 
V 
indicated that UGT1A8 has overlapping substrate specificity with UGT1A7. UGT1A8 
can be induced by 18 GA and licorice. The study provides useful information on the 
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Chapter One. Introduction 
1.1 Drug metabolism and UGTs 
Drug metabolism is one of the most important processes in the liver. The drug 
metabolizing process can be divided into two steps: phase I reaction and phase 
II reaction. When different drugs and chemicals enter cells by passive diffusion 
or with the actions of uptake transporters, phase I enzymes, mainly cytochromes 
P-450 (CYPs), would convert them into nucleophilic phenols, polyphenols or 
electrophiles, such as epoxides and quinones, which would then be conjugated 
by phase II enzymes, such as UDP glucuronosytransferase (UGT) and 
sulfotransferase (SULT) or glutathione S-transferase (GST). The resulting 
hydrophilic organic anions are removed from the cell by export transporters. 
UGTs represent major phase II drug metabolizing enzymes (DMEs), 
conjugating a wide variety of drugs, such as external chemicals like dietary 
phytoalexins and endobiotics like bilirubin and steroid hormones. Glucuronic 
acid conjugation dictates the elimination of those chemicals, and the action is 
determined by the UGT contents of different cells and tissues. There are 
obvious inter-individual differences in the amount and expression level of UGTs 
in liver and other organs. The drug metabolizing enzymes convert lipid-soluble 
compounds into water-soluble and excretable forms. A group of drug 
1 
metabolizing enzymes (DMEs) rapidly interconvert nucleophiles and 
electrophiles, for example, NQOl and peroxidases. The balance between phase 
I and II enzymes often determines the accumulation of reactive intermediates 
which may cause oxidative/electrophile stress and toxicity. The latter often 
initiates the covalent binding of metabolites to DNA and protein. Hence, when 
dealing with UGT functions, glucuronide transporters and compensatory 
enzymes, for examples, sulfotransferases (SULTs), have to consider the balance 
and control of these types of reactions, which are very important in the 
homeostasis of the body. 
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Figure 1. Reaction catalyzed by the enzyme UDP-glucurono sytransferase. The 
substrate, after the conjugated with UDPGA, would become more water soluble. The 
increase in the solubility of substrate can enhance the excretion of it through urine. 
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1.2 Natural substrates of UGTs 
Phytoalexins are antimicrobial compounds produced in plant cells exposed to 
bacteria and fungi. They are important in protecting plants against insects and 
other animal predators. Many of them act as polyphenolic pro/antioxidants, 
such as quercetin, present, for example, anthocyanidine, the red color of roses 
Ford et al 1998], in onions and in honey [Galijatovic et al, 2000], the 
phytoestrogen resveratrol in grapes and wine [Gehm et al, 1997], and 
zeaxanthin in bacteria [Hundle et al, 1992]. They are stored in plant cells and 
bacteria as glucosides which are readily hydrolyzed. Vertebrates take in these 
plants and so the UGT in the liver and in the intestinal tract would provide a 
protective role to neutralize these different phytoalexins. In the gastrointestinal 
(GI) tract and the liver, the protective role of UGTs is indicated by their large 
numbers and high expression levels, including the specific expression of some 
isoforms, such as UGT1A7 in the human upper GI tract (orolaryngeal mucosa, 
esophagus, and stomach) and UGTIAIO in the small intestinal and the colon 
mucosa [Tukey et al, 2001]. This protective function may be most relevant at 
earlier stages of evolution when fish and terrestrial animals tried to live on a 
plant diet, and plants developed phytoalexins for survival, a process termed 
'animal-plant warfare' [Nebert et al, 1990]. 
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Figure 2. Chemical structures of some phytoalexins and antioxidants. They are some 
common substrates of the enzyme UGTs. 
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1.3 Functions of U G T isoforms: roles of U G T polymorphisms 
UGTs work at several different levels in the organism: in presystemic or 
systemic drug metabolism and locally within various types of cells. It is known 
that a number of factors control glucuronide formation and disposition in cells 
and in the whole organism. Nevertheless, when using isoform-specific probe 
substrates, in vitro microsomal UGT activity correlates well with in vivo 
glucuronide formation. For example, the interindividual hepatic bilirubin UGT 
activity correlated with the blood level of bilirubin in Gilbert individuals 
[Raijmakers ct al, 2000] and the morphine UGT activity with presystemic 
glucuronidation of oral morphine [Save et al, 1985]. Locally, UGT activity has 
been shown to be important, for example, in controlling steroid hormone levels 
[Sun et al, 1998]. Therefore, the in vitro analysis of UGT activity is very 
important for prediction of in vivo metabolic clearance [Mistry et al 1987 and 
Soars e t a m ^ l X 
Certain polymorphisms have been discovered in UGT families 1 [Mackenzie et 
al 1997]. In the UGTl locus a TATA box mutation of bilirubin-metabolizing 
UGTlAl, leading to a reduced enzyme activity, has received a lot of interest 
since it is frequently related to Gilbert's syndrome in Caucasians [Bosma et al 
6 
1995 and Monogan et al 1996]. In addition to be exposed to mild 
hyperbilirubinemia, Gilbert individuals have shown unwanted side effects of the 
chemotherapeutic agent irinotecan since its effective major metabolite SN38 is 
mostly inactivated by UGTlAl , thus resulting in intoxication [Ando et al 1998, 
Ando et al 2000]. Repeated sequences, such as A(TA)nTAA, in the promoter of 
UGTlAl are unstable and tend to lengthen or shorten as a result of unequal 
crossing over in meiosis. It has been shown that increasing TA repeats of the 
UGTlAl TATA box alters the transcription, enzyme level, and activity [Beutler 
et al 1998]. The allelic variants A(TA)6TAA (UGTlAl*：!) and A(TA)7TAA 
(UGTlAl 28) are frequent in different populations. Bilirubin may be either 
harmful or beneficial; severe hyperbilirubinemia in neonates is known to cause 
kernictems and brain damage. However, low bilirubin level together with high 
biliverdin reductase activity appears to be a powerful antioxidant [Baranano et al 
2002]. In fact, Gilbert individuals seem to be protected from coronary heart 
disease [Vitek et al 2002]. The levels of UGTs and the body condition have 
complicated relations. There are still major differences in allele frequencies 
among ethnic groups. For example, the frequency of UGTlAl'28 was found to 
be ca. 0.29 in Caucasians and 0.26 in Egyptians [Kohle et al 2003] and only ca. 
7 
0.09 in Japanese [Hall et al 1999]. Hence, the disease conditions of different 
races would vary. 
1.4 Evolution of the U G T l gene locus in vertebrates 
The organizations of human and rat UGTl gene locus show considerable 
similarities to each other. (FigureS). It is believed that the gene was present 
before the radiation of rodents and man, before the beginning of the age of 
Paleocene, i.e. 65 million years ago [Strickberger M.W., 2000]. This gene locus 
was also found in many other mammalian species, for example, rabbit, monkey, 
dog, mouse and sheep. Herbivorous lagomorphs have evolved duplicated 
UGT1A6 genes in their UGTl locus [Li et al, 2000]. The detoxification of 
dietary plant polyphenolic phytoalexins, which have been discussed before, and 
the degradation of phytoestrogens (which share similar structure with steroid 
hormones) are believed to be the evolutionary driving force for the generation 
of the UGTl locus. [Nebert et al 1990, Gehm et al 1997]. Certainly, sex 
hormone-like phytoestrogens would greatly affect the reproduction of 
organisms. Prey-predator relation represents a major process in evolution. That 
is, herbivorous predators evolved phytoalexin detoxifying enzymes and these 
adaptively generated phenol UGTs were no longer necessary in carnivorous 
8 
species because their prey (cattle, sheep, etc.) had already done the job of 
detoxifying phytoalexins. For example, in carnivorous cats and leopards 
UGT1A6 was found to be present as a pseudogene [Court et al, 2000:. 
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Figure 3. Organization of the human and rat UDP-glucuronosyltransferase-1 gene 
locus; P, pseudogenes; Tl , transcription unit 1; T2, transcription unit 2 (Adapted 
from Bock, 2003). The expression of different isozymes is highly controlled. AhR is 
one of the regulatory components of UGTs. 
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Conjugation of compounds, including steroids, by glucuronidation has been 
demonstrated in all vertebrates studied to date. This reaction, which corresponds 
to the transfer of the glucuronosyl group from UDP-glucuronic acid to small 
hydrophobic molecules, is catalyzed by enzymes of the UGT superfamily. The 
resulting glucuronide products are more polar, generally water soluble, less 
toxic and more easily excreted from the body than is the parent compound. 
More than 45 different UGT cDNA clones have been isolated from seven 
mammalian species, including 18 human UGT clones [Court et al 2000 and 
Clarke et al 1992]. Based upon homology of primary structures, the UGT 
proteins have been categorized into two families, UGTl and UGT2, with UGT2 
being subdivided into two subfamilies, UGT2A and UGT2B (Figure 4). 
Members of the UGTl family share >50% identity with each other, but <50% 
identity with members of the UGT2 family. 
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Figure 4. Phylogenetic tree of the 18 human UDP-glucuronosyltransferases (UGTs). 
The UGT proteins have been categorized into two families, UGTl and UGT2, with 
UGT2 being subdivided into two subfamilies, UGT2A and UGT2B. Amino acid 
sequences of human UGTl A and UGT2B enzymes were from the GenBank database. 
UGT1A2, UGTl All, UGT1A12 and UGT1A13 are pseudogenes. The human UGT2B 
enzymes isolated to date are named according to their chronological order of 
isolation. Five human UGT2B pseudogenes have also been isolated, whereas 16 
UGT2B enzymes have been characterized in rats, monkeys and rabbits. 
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1.5 Multiple Variable First Exons: A Mechanism for Cell- and 
Tissue-Specific Gene regulation. 
The organization of UGTl was studied for the multiple variable first exon. This 
genomic organization provides genetic multiplicity for generating diversity. In 
the cases of UGTl genes, the variable exons are very similar to each other and 
encode diverse polypeptides. 
A tandem array of UGTl variable exons, encoding highly similar but distinct 
polypeptides, provides a means for generating such diversity. UGTl proteins 
are typical type I transmembrane proteins, that is, they have a single 
transmembrane segment located close to the C terminus. The oligomer structure 
of UGTl proteins may provide diverse substrate specificity (lyanagi et al. 1998). 
The UGTl genes, each variable exon only encodes the N-terminal half of the 
protein, without a transmembrane segment. In contrast, the constant region 
encodes the C-terminal half of the protein, including the transmembrane 
segment (lyanagi et al. 1998). Thus, a single variable exon itself does not appear 
to encode a functional UGTl protein. In addition, by using the BLAST program 
we searched the human, mouse, and rat EST and cDNA databases with intron 
sequences immediately downstream from each variable exon, but could not find 
13 
any transcripts that contain a variable exon and its immediately downstream 
intron sequences. A similar search for the Pcdh clusters reveals many such 
transcripts. Therefore, unlike Pcdh clusters, the UGTl cluster does not have 
variable-only forms of diversity. 
1.6 Evolutionary Origin of the Variable and Constant Genomic 
Organization 
The variable exons aligned raise important implications regarding the 
evolutionary flow. For the UGTl cluster, the variable exons of the bilirubin and 
phenol groups appear to be duplicated separately from two congenital variable 
exons (Figure 5), which are themselves repeated from a single congenital 
variable exon. Some variable exons, for example, mouse UGT1A12 and A13, 
are believed to result from species-specific amplification of the same variable 
exon. Different from the case of UGTl gene locus, the duplication of the IGnT 
variable exons occurred before the disrehtion of the human, mouse, and rat, 
because the three variable exons reveal totally orthologous relationships. 
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Figure 5. Similar genomic organization of UGTl gene clusters. Shown are 
comparisons of the genomic organization of mouse, rat, and human UGTl clusters. 
Each cluster has multiple, highly similar, tandem variable exons followed by one set 
of constant exons. They are indicated by vertical colored bars: (green) phenol-type 
UGTl variable exons; (orange) bilirubin-type UGTl variable exons; (blue) 
pseudogenes or relics (present in both Pcdh and UGTl clusters); (turquoise) 
non-UGTl genes in the UGTl cluster; (pink) constant exons (present in both Pcdh 
and UGTl clusters). The approximate length of each cluster is shown below the 
corresponding panels. The pseudogenes are represented by a letter "p" following the 
gene symbol, whereas the relic sequences are represented by a letter "r." (Pcdh) 
Protocadherin; (UGT) UDP glucuronosyltransferase; (Hsp40L) heat-shock protein 
40kd like gene. 
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For variable exons that reveal high similarities，the unit of repeat appears to 
include both the coding sequence and its upstream regulatory region. For UGTl, 
within a certain cluster, the coding regions of multiple variable exons not only 
share exact sequence, but also have a similar number of amino acids residues. 
In fact, the conserved sequence motifs are upstream from the variable exon of 
each clusters (Wu et al. 2001). However, a large part of the regulatory 
sequences have been diversified. For example, the flanking sequences of the 
highly conserved motifs are different among distinct variable exons. This 
heterogeneity shows tissue specific or cell specific type of gene expression in 
order to interact with development process and the change in the environment. 
In some cases, however, for example, Pcdh 计6 and yb7, the promoter 
sequences show high homogeneity. This exception was found to be the 
consequence of selective pressure during evolution or simply not enough time 
for the diversification after the repeat of the cluster; however, this case rarely 
shows in the UGTl gene cluster. 
In the cases the transcriptional direction for variable exons is the same, that is, 
towards the C terminal constant region. Even in the cases of pseudogenes or 
relics, the remnant codons are always on the same DNA strand. This shows an 
exon repeating process that can exclusively result in a parallel contingent 
16 
arrangement. In addition, this may also demostrate that the parallel arrangement 
of variable exons and their promoters ensures that the functional mRNAs can be 
formed by the cz^-splicing mechanisms. 
A number of models have been proposed to explain the conservation of 
duplicated genes. The classical model for the evolution of repeated genes 
hypothesized that paralogous genes arise by gaining new adaptive functions 
(Ohno 1970). Recently, the duplication-degeneration-complementation (DDC) 
model hypothesized that paralogous genes achieve interconnected subfunctions 
of the familial gene (Force et al. 1999). The organization of UGTl is unusual in 
that only the first exon was duplicated. Anyway, this organization supports both 
different aspects of the two models. The vast expansion of variable exons by 
organized arrangements in the UGTl clusters may reflect the narrow-down 
selection for the numbers of possibilities required for detoxification. On the 
other hand, the prototypical UGTl genes may have been expressed ubiquitously 
and had much broader functions in the past. 
Compared with variable exons that do not show sequence similarity, such as in 
the plectin, NOSl, and GR genes, selective splicing that joins a cap-proximal 5' 
splice site to the 3' splice site of the first constant exon removes all the introns. 
17 
Hence, specific promoter initiation and cap-proximal cw-splicing may have 
evolved for this type of multiple regulatory strategies. In this case, the 
duplication of UGTl variable exons, would come to the same evolution for 
arrays of multiple first exons. At the same time, the origin of aligned tandem 
was from varying first exons. It was very likely that this organization provides a 
genetic mechanism for the diverse gene regulation required for complex 
mammalian development and adaptation. 
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Figure 6. Phylogenetic tree of human, mouse, and rat UGTl gene clusters. The tree 
was reconstructed based on variable region polypeptides by using the 
neighbor-joining method of the CLUSTAL W package. The tree branches are labeled 
with the percentage support for that partition based on 1000 bootstrap replicates. The 
scale bar equals a distance of 0.1. [Adapted from Zhang et al 2003: 
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1.7 Variable and Constant Genomic Organizations Exist in Mammalian 
UGTs 
High throughput genomic sequencing has enhanced the process of annotating 
sequences. To date, DNA sequencing of cDNA clones is still the most reliable 
method to identify unknown genes. Although EST sequencing can give 
valuable information about the annotation in a given genome, it is usually not 
possible to provide reliable information about the 5'-end of genes since most 
ESTs are derived from the 3'-end. Recently, the Institute of Physical and 
Chemical Research (Japan; RJKEN) has sequenced 60,770 full-length mouse 
cDNA clones (http://fantom2.gsc.iiken.go.jp/; Okazaki et al. 2002). This large 
amount of data still provides limited information on the study of the UGTl gene 
cluster, allowing a further study of the genes. 
1.8 The history of recombinant U G T expression 
Twenty years ago, it was difficult to study UGTs in the liver. It required a 
freshly separated tissue, usually an ox liver. The purification of the protein was 
one of the most time consuming step. The purification technique was not 
advanced enough to give a homogeneous protein. The study was not significant 
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enough since the data was from a species distant from us. The characterization 
of the UGT isoforms was greatly enhanced by the modem technology of 
cloning and recombinant protein expression. The study of an enzyme was 
greatly enhanced when a large amount of the protein can be expressed and 
purified. Recombinant protein expression in E.coli provides a low-cost and 
efficient means for protein study. In 1988, Harding D. et al successfully 
expression phenol-UGT in mammalian culture for the first time (Harding et al 
1987). Since then, the study of the family has been rapidly remedied by the 
recombinant expression. The study of substrate specificity of different isoforms 
can be achieved. The isoform UGTlAl, UGT1A6, UGT1A7 etc. were also 
studied through this way. In this study, bacterial expression system was used. 
1.9 UGT1A8 
Rat UGT1A8 was first detected in 2002 in our lab [Leung et al, 2002]. It was 
found with the induction of 3-methycholanthrene in rat hepatoma cells. In 2003, 
the tissue expression of this protein in rat was found [Shelby et al, 2003]. 
However, the range of inductive agents and the properties of this newly 
identified protein remained unknown. A more detailed study of the protein 
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would provide insights into UGT. The rat UGT1A8 shares high homology 
(higher than 80%) amino acid sequence homology with human UGT1A8; 
however, the major site of human UGT1A8 expression is the intestine. 
22 
1 ^ 1 UGT1A8 "Male 
2 4 - * _ Female 
1 3 - 1 
< o 圓 女 
§ 终 ^ • pi 
H 各 • M'^i l — J t t i 
- - / / / / / / / / 
、 。 令 / / / / / 
Figure 7. Tissue distribution of rat UGT1A8, liver and kidney were found to be the 
major site expressing the protein. Female rats showed a higher level of UGT1A8 
expression when compared to male rats [Shelby et al, 2003] 
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1.10 Licorice and its active component 
The word "licorice" originated from Greek words “glyks，，，meaning sweet and 
rhiza meaning root. It is the sweet tasting rhizomes that are used as flavourings. 
Licorice is native to south-eastern Europe and the Middle East, where it grows 
in the wild. Chinese herbalists have long been using licorice, concentrating the 
root's extract and prescribing it for a wide range of conditions. The root 
contains vitamin E, B-complex, biotin, niacin, pantothenic acid, lecithin, 
manganese and other trace elements. It also has beneficial medicinal qualities. 
Licorice Root has been used as a laxative; to adjust blood sugar, reduce pain 
from ulcer and arthritis. It has been shown that chewing licorice root has been 
very helpful in giving up smoking as it gives the hands something to do and has 
the shape/texture of a cigarette. 
Many researchers have shown that licorice helps treat and relieve pains that 
accompany certain types of ulcers, with more and more researchers gaining 
positive results with its use as an ulcer treatment. Licorice is getting more 
popular in North America. Licorice is shown to have anti-inflammatory 
properties [Kawakami et al, 2003, Amaryan et al, 2003] and may therefore help 
relieve the discomforts that accompany arthritic conditions. 
18(3 glycyrrhetinic acid, one of the active components of licorice, has known to 
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possess pharmacologic effects. It is most well known for its anti-inflammatory 
properties, which can inhibit the prostaglandins metabolizing enzymes. It is also 
known as a hepatoprotective agent. However, the mechanism of 
hepatoprotection is still unclear but it is believed that the chemical can induce 
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Figure 8. Structure of 18(3 glycyrrhetinic acid 
1.11 Enzyme induction in the liver 
Liver is the primary site for xenobiotics metabolism. Different nuclear receptors 
like aryl hydrocarbon receptor (AhR) and orphan nuclear receptors have been 
shown to be the key mediators of drug-induced changes in phase I and phase II 
metabolizing enzymes. It is well known that the expression of CYPl genes can 
be induced by AhR, which can dimerize with the AhR nuclear translocator, due 
to the presence of many poly cyclic aromatic hydrocarbons. Similarly, orphan 
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nuclear receptors, the constitutive androstane receptor (CAR) and pregnane X 
receptor (PXR), both form hetero-dimers with the retinoid X receptor (RXR), 
and are shown to transcriptionally activate the promoters of CYP2B and 
CYP3A gene by xenobiotics such as phenobarbital and dexamethasone and 
rifampin family agents. The peroxisome proliferator activated receptor (PPAR), 
which is one of the first characterized members of the nuclear hormone receptor, 
also dimerizes with RXR and shown to be activated by cholesterol reducing 
agent leading to transcriptional activation of the promoters on CYP4A gene. 
CYP7A was discovered as the first target gene of the liver X receptor (LXR), in 
which the elimination of cholesterol depends on CYP7A. The physiological and 
the pharmacological implications of common partner of RXR for CAR, PXR, 
PPAR, LXR and FXR receptors largely remain unknown and are under lots of 
studies. For the phase II DMEs, there are plenty of phase II gene inducers, for 
example, the phenolic compounds butylated hydroxyanisol (BHA), 
tert-butylhydroquinone (tBHQ), green tea polyphenol (GTP), 
(-)-epigallocatechin-3 -gallate (EGCG) and the isothiocyanates (PEITC, 
sulforaphane) generally appear to be electrophiles. They all possess 
electrophilic-mediated stress response, resulting in the initiation of transcription 
factors Nrf2 which dimerizes with Mafs and binds to the 
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antioxidant/electrophile response element (ARE/EpRE) promoter, which is 
located in phase II DMEs as well as many cellular defensive enzymes, with the 
successive induction of the expression of these genes. Along with phase I and 
phase II enzyme induction, pretreatment with several kinds of inducers has been 
shown to alter the excretion of the xenobiotics, which reflects that transporters 
may also be regulated, at the same time gives an important way to protect the 
body from chemical insults. The stress would lead to the increase in gene 
expression, which eventually enhances the elimination of these xenobiotics and 
reactive oxygen species (ROS). The induction of UGTs belongs to the induction 
of the phase II enzyme, and the detail of the induction is lacking. A novel gene 
of UGTl A8 was discovered in the rat hepatoma cell-line [Leung, et al, 2002]. It 
has been shown that the gene can be induced by some polyaromatic compounds. 
However, in vivo study is required for a better understanding of the induction 
process in an organism. 
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1.12 Objectives 
The biochemical functions of the newly identified UGT1A8 in rat are lacking. The 
present study was aimed at 
1. To quantitatively prepare UGT1A8 in E.coli expression system; 
2. To purify the enzyme; 
3. To understand the biochemical properties of UGT 1A8 
The study would provide useful information on the functional roles and substrate 
specificity of UGTl A8 in detoxification. 
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Chapter Two. Materials and Methods 
General Procedure 
The project was divided into two main parts: UGT1A8 induction in in vitro and 
in vivo systems and recombinant UGT1A8 expression in E. coli. In the first part 
of the project, the inductive effects of licorice and 18(3-glycyiThetinic acid on 
UGT1A8 were studied with two types of liver cells: clone 9 (isolated from rat 
epithelial cells of normal liver) and H4IIE (isolated from rat liver hepatoma). 
The results in in vitro study were confirmed with two types of rats: Wistar (rats 
commonly used for the study of liver metabolism) and j/j (rats with UGT 
deficiency). Livers of treated rats were isolated and the expression levels of 
UGTs were investigated with RT PGR and Northern blot analysis. In the protein 
expression experiment, the rat liver UGT1A8 coding fragment was isolated and 
cloned into prokaryotic expression system. Recombinant protein expression was 
performed with E.coli (strain JM109) system in order to prepare sufficient 
amount of protein for further studies. The purified protein was characterized for 
its substrate specificity. 
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2.1 UGT1A8 induction studies 
2.1.1 Preparation of inducers 
The dried herb was purchased from a local store and used for the whole project. 
Licorice (50 grams) was soaked in 500 ml of distilled water for one hour and 
boiled to a final volume of 100 ml in two hours. The extract was kept in 4�C 
before rat feeding. 18(3-glycyrrhetinic acid was dissolved in nano pure water. 
The solution was also kept at 4�C in a fridge before use. All the reagents were 
discarded after one month to prevent any auto-degradation. Reagents that used 
in cell culture experiments were 0.2jam syringe-filtered just before use. 
2.1.2 Cell viability study with Neutral Red Assay 
Rat hepatoma cells (H4IIE) and rat liver epithelial cells (clone 9) were 
previously purchased from ATCC and used to study UGT1A8 induction. Cells 
were seeded with a 96-well format (5000 cells in each well) and after 
incubation for twenty four hours, different concentrations of drug were added to 
the cells. After the desired incubation period of time, the plates were harvested. 
First, wells were washed with 0.2mL of IXPBS, and then 0.15mL of 5mg/mL 
neutral red (Sigma) solution was added. The plate was allowed to be further 
incubated at 37°C for two hours in incubator. The solution was removed and 
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the plate was allowed to dry overnight in a 55�C oven. The red pigment was 
resuspended in 1% SDS just before spectrophotometric measurement at 545nm. 
2.1.3 Cell treatment 
Cells were seeded 24 hours before the addition of drugs with 100mm dish 
format (0.5 x 10^ cells). The desired amount of drug was added to the plate and 
incubated for different periods of time. RNA was extracted and analyzed for the 
expression of the target gene. 
2.1.4 Rat treatment 
Both wistar rats (weighing around 200gram) and j/j (weighing around 200gram) 
rats were divided into three groups, with five rats in each group. The dosage of 
the licorice extract was 20mg/kg/day and 160mg/kg/day of 1 Sp-glycyrrhetinic 
acid for the treatment group to yield the over-expression of UGTl A8. Rats in 
the control group received water instead. 
2.1.5 RNA extraction from rat liver and cell culture 
Rat liver RNA was extracted with Trizol reagent (Invitrogen) with an 
established protocol. Briefly, 100 mg of liver tissue or one 100 mm dish of cells 
31 
was homogenized with 1 mL Trizol reagent. The sample was subjected to 13000 
X g for fifteen minutes at 4°C ； the supernatant was taken and mixed with 0.2mL 
of chloroform. The sample was vortexed and allowed to stand at room 
temperature for ten minutes. The process was followed by centrifugation 
(13000 X g) for fifteen minutes at 4°C. The supernatant was taken and mixed 
with ImL of isopropanol. The mixture was allowed to stand for fifteen minutes 
at -20°C, followed by centrifugation (13000 x g). The pellet was washed with 
75% ethanol and air dried. The pellet was subsequently dissolved in 45 //1 of 
DEPC-treated water. The samples were stored at - 2 0 f o r less than three 
months. 
2.1.6 Quantization of RNA 
RNA was diluted to 1000 fold with IXTE buffer, pH8.0 and the optical density 
was measured at 260nm with a Beckman DU650 spectrophotometer. It is 
known that OD260 times the factor 40 would be equal to the RNA concentration. 
Each RNA sample was measured three times and the average reading was taken 
for RNA concentration. 
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2.1.7 Denaturing gel electrophoresis for RNA 
The gel consisted of 1.5% agarose, 0.04mM MOPS and 6.8% formaldehyde. 
RNA was sepearated by electrophoresis at lOOV for thirty minutes. The 
resultant gel was stained with O.lmg/ml ethidium bromide and observed under 
UV. Both 28S and 18S RNA bands were observed as an indicator of RNA 
integrity. 
2.1.8 Northern hybridization 
RNA (30|ig) was separated in a 1.5% denaturing gel. RNA was transferred to 
Hybond-N+ (Amersham Bioscience) membrane by capillary force overnight. 
RNA was immobilized by a UV cross-linker with maximum power for thirty 
seconds. The membrane was hybridized with ^^P-labelled cDNA probe at 65�C 
for two hours, followed by thirty minutes of wash with 2XSSC, 0.1% SDS at 65 
�C, two rounds of twenty minutes of 0.2XSSC with 0.1% SDS wash at 65 
and 2XSSC at room temperature for five minutes. The membrane was subjected 
to autoradiography at -70�C for sixteen hours. The densities of the bands were 
analyzed with ImageJ imaging program. 
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2.1.9 Probe for Northern Blotting 
DNA probe was synthesized with PGR. The sequence of the probe was checked 
with DNA sequencing. Radioactive labeling was performed with Rediprime 
labeling kit (Amersham Bio Science). 
2.1.10 Agarose Gel analysis and Northern Blot analysis 
Gel photos and exposed films were scanned with Epson Perfection® 3170 
Scanner. Gel analysis was performed by the software Image J (NCBI). Film of 
Northern blotting was also scanned and analyzed by the software. 
Table 1. Sequences of primers used in RT-PCR 
Forward primer Reverse primer 
UGT 1A1 5' acaccggaactagaccatcgS’ 5’ tgggtcttggatttgtgtgaS’ 
UGT 1A7 5' ttcaccatgcagatggttgtS‘ 5, ctgggcagggctagtcagta3， 
UGT1A8 5' atggctccttcaggctgtcS' 5 ‘ actttcccatgtgccaactc3 ‘ 
(3actin 5 ’ agccatgtacgtagccatccB ’ 5 ’ ctctcagctgtggtggtgaaS, 
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2.2 Recombinant expression of U G T l A8 in E.coli JM109 
2.2.1 cDNA synthesis 
RNA (3jig) was mixed with 0.5mM dNTP mix, IX reaction buffer and 200 
units MMuLV reverse transcriptase (Amersham) and incubated at 37°C for 45 
minutes. Autoclaved water (20|i,L) was added to dilute the mixture. Synthesized 
cDNA samples were stored at -20°C until use. Samples were not stored for 
more than half a year. 
2.2.2 Polymerase chain reaction 
Polymerase chain reaction was performed with 1 |iL of cDNA, 1X PCR buffer, 
0.75mM MgCli, 0.6|iM sequence specific primer, lU of Taq DNA polymerase, 
followed by different PCR conditions with ABI GeneAmp ® 9700 thermocycler. 
2.2.3 Agarose gel electrophoresis for DNA 
Agarose (Amersham Biosciences) was added to 0.5X TBE to a final 
concentration of 1.5%, Ethidium bromide (USB) was added to a final 
concentration of 0.05jig/mL. DNA was separated at a constant voltage of 120 V 
for twenty minutes. The gel was visualized with a gel documentation system 
(UVItec). 
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2.2.4 Amplification of target gene, UGT1A8 
UGT1A8 insert was amplified from liver cDNA with UGT1A8 specific primers 
(forward: 5’ ctcgagatggctccttcaggct 3'; reverse: 5’ aagctttcagtgggttcttg 3') under 
the following conditions: 94�C for five minutes; 94�C for forty five seconds, 
55�C for forty five minutes, 72°C for one minute and thirty seconds for 28 
cycles; 72�C for ten minutes with Pfu polymerase (Promega). The amplified 
DNA fragment was purified with Nucleospin DNA purification kit (BD Falcon) 
and used as template for another round of PGR with the same conditions. The 
DNA was quantified; part of the sample was taken for restriction enzyme 
digestion. 
2.2.5 Restriction enzyme digestion of plasmid and insert 
pRset (Invitrogen) plasmid (l|ag) or PGR product was mixed with Img/mL BSA 
and IX buffer and incubated with lU of Hindlll and Xhol (New England 
Biolab) in a 37°C water bath for one hour. Sample was analyzed by an agarose 
gel to confirm complete digestion. The resultant DNA fragment was purified by 
Mini-M gel purification system (Viogene). 
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2.2.6 Ligation of plasmid and insert DNA 
The digested plasmid and DNA fragment was incubated at 4°C with lOU of T4 
DNA ligase (New England Biolabs) with IX T4 ligase reaction buffer in a 20[iL 
reaction for eighteen hours. 
2.2.7 Amplification of target plasmid 
The total 20 fiL ligation reaction was used in the transformation of DH5a 
competent cells (Invitrogen). The DNA was first incubated with the cells for 
twenty minutes on ice. Immediately, the whole mixture was placed in a water 
bath at 42°C and subjected to heat shock for exactly 45 seconds. The bacteria 
were allowed to recover on ice for 5 minutes. Then LB medium (500|jL) was 
added to the mixture and the whole reaction was incubated at 37�C for one hour. 
Bacteria (50jiL) were spread on a LB plate containing 1 OOjLig/mL ampicillin. 
The plate was incubated for 16-18 hours at 37�C. 
2.2.8 Screening of target plasmid 
Twenty colonies of bacteria were randomly picked and grown in 5 mL LB 
medium with lOOp^g/ml ampillcin for ten hours. The bacterial cells were taken 
for plasmid extraction with plasmid Mini-M purification kit (Viogene). The 
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DNA was taken for restriction digestion. Plasmid that can be digested into two 
and with the expected size was taken for DNA sequencing for further 
confirmation of the insert. 
2.2.9 DNA sequencing 
DNA sequencing was performed by Tech-Dragon Company which provided the 
service. The result was checked by NCBI (BLAST) for the identity. 
2.2.10 Transformation of protein expression host 
The confirmed plasmid was used to transform protein expression host JM109. 
The procedure was similar to the one described previously. 
2.2.11 Confirmation of transformation of protein expression host 
Transformed colonies were randomly selected and picked out for colony PCR 
with the following conditions: single colony was picked and mixed with IxPCR 
buffer, 1 ！1M gene specific primer, ImM magnesium chloride, 0.2mM dNTP 
mix, lU of Taq DNA polymerase. Clones that showed the expected band were 
inoculated into LB medium. 
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2.2.12 Protein expression 
Bacteria were cultured to mid-log phase before IPTG induction. When the 
OD600 of the culture was between 0.4 and 0.6, a final concentration of 0.5mM of 
IPTG was added to the culture and six hours later the cells were harvested by 
centrifugation. Successful protein expression was confirmed by SDS-PAGE 
showing protein bands with expected size (55kDa). 
2.2.13 Protein purification 
Bacterial cells were harvested by centrifugation at 5000xg for 20 minutes. Cell 
pellet was resuspended in binding buffer (O.IM Tris-HCl buffer, pH8.0). The 
cells were lysed by sonication on ice. The mixture was centrifuged at 5000 x g 
to remove unbroken cells and large debris; then the sample was further 
centrifuged at 12000 x g to remove any remaining debris. Protein purification 
was performed with a Ni+ column. The sample was allowed to bind with the 
matrix at 4 � C for one hour. Then the matrix was washed with 10 volumes of 
binding buffer under gravity to remove any unbound protein. After this, the 
matrix was washed with five volumes of washing buffer (with lOOmM 
imidazole). The protein of interest was eluted with three volumes of elution 
buffer (with SOOmM imidazole). The protein was collected in fractions of 
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0.5mL • 
2.2.14 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE containing 0.1 % SDS was performed in 12 % slab gel according to 
the method of Laemmi (Laemmi, 1970). BioRad Mini-PROTEAN system was 
employed for electrophoresis. Precipitated samples were incubated in 
SDS-PAGE sample buffer (125 mM Tris-HCl, pH6.8, 1 %w/v SDS, 5 %v/v 
glycerol, 10 mM dithiotheritol) at boiling temperature for 5 minutes. Protein 
marker (BENCHMARK™ Jnvitrogen) was used. Protein bands were stained 
with Coomassie brilliant blue R-250 (Boehringer Mannheim) in fixing solution 
of 30%v/v ethanol (Merck) and 10 %v/v acetic acid (Merck) for 30 minutes. 
Stained gel was destained in destaining solution (30 %v/v ethanol, 10 %v/v 
acetic acid) till protein bands were visible. 
2.2.15 Confirmation of the protein 
Different fractions of the chromatography were analysed by SDS-PAGE to 
check for the target protein. A protein band at 55kDa was believed to be the 
target protein. 
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2.3 Characterization of recombinant UGT1A8 
2.3.1 UGT assay 
UGT assay was performed under the following condition: O.IM Tris HCl, 
pH7.4, 3mM UDPGA, 5mM MgCb and 50^M of the substrate. The mixture 
was pre-incubated at 37°C for 5 minutes followed by the addition of the purified 
target protein. After 30 minutes of incubation, the reaction was stopped by 
NaOH. The concentration of the substrate was measured. The substrate 
concentration was determined using a standard curve. 
2.4 Routine experiment methods 
2.4.1 Determination of protein 
A commercial kit, purchased from BioRad, was employed for the determination 
of protein. This assay kit was based on the method described by Bradford 
(Bradford, 1976). In each determination, protein samples were diluted with 
water, to make up a volume of 800 \xL A volume of 200 jil of the assay dye was 
added. Color development was allowed for 5 minute. Absorbance was measured 
at 595 nm. 
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2.4.2 Nucleic acid purification 
PCR products were purified by using Nucleospin gel purification kit (BD 
Biosciences) according to procedures supplied by the kit manufacturer. For 
products excised from agarose gel, agarose gel was dissolved in NTl buffer 
supplied at 55°C. For any PCR products in solution form, the volume of 
solution was first added to 100 |il by TE buffer (0.01 M Tris, 1 mM EDTA, pH 
7.4) before mixing with NT2 buffer. Samples were loaded to a spin column, 
which was washed twice with NTS buffer. Nucleic acid was eluted from column 
by NE buffer (5 mM Tris-HCl, pH 8.5) which had previously warmed (55°C). 
2.4.3 Preparation of chemically competent bacterial cells 
Competent cells were prepared by rubidium chloride method. One ml of culture 
of competent cells grown overnight was inoculated into 100 ml Psi broth (5 g/L 
bacto yeast extract, 20 g/L bacto tryptone, 5 g/L magnesium sulfate, pH 7.6). 
The culture was grown at 37°C with aeration until OD550 reached 0.4. The 
culture was cooled for 15 minutes. Cells were collected by centrifugation at 
5,000 g for 8 minutes. The pellet obtained was resupended in Tfbl buffer (30 
mM potassium acetate, 100 mM rubidium chloride, 10 mM calcium chloride, 
50 mM manganese chloride, 15 %v/v glycerol, pH 5.8) and iced for 15 minutes. 
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After incubation, centrifugation was carried out at 5,000 g for 8 minutes. The 
pellet was respended in Tfbll buffer (lOmM MOPS, 75 mM calcium chloride, 
10 mM rubidium chloride, 15 %v/v glycerol, pH 6.5). Resupended cells were 
quickly frozen in liquid nitrogen, and stored at -80°C. These cells were now 
ready for transformation by heat shock. 
2.4.4 Colony PGR 
Bacterial colonies were picked and lysed in lysis buffer (TE buffer, pH 8.0, 0.1 
% Tween 20) at boiling temperature for 10 minutes. Plasmid DNA released was 
used as the template for the subsequent PGR. A primer pair flanking the 
multiple cloning site of the plasmid was used. Each reaction contained 1 mM 
dNTP mixture, 0.25 jiM primers and 0.2 |il Taq polymerase (Sangon). The 
reaction was performed in reaction buffer supplied by manufacturer. The PGR 
mixture was incubated at 94°C for 3 minutes followed by 30 cycles of 
amplification. Each cycle consisted of 45 seconds of denaturation at 94°C, 1 
minute of annealing at 55°C and 1 minute of extension at 72�C. A final 
extension step of 72°C for 10 minutes was performed after thermo-cycling had 
been completed. 
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2.4.5 Plasmid rescue by alkaline lysis 
Plasmids were purified from overnight-cultured competent bacterial cells by 
alkaline lysis method. The Rapid Plasmid Minipreps system (Marligen) was 
employed in this work. Cells were collected by centrifugation at 10,000 g for 2 
minutes. Any pellets obtained were suspended in cell suspension buffer (50 mM 
Tris-HCl, pH 8.0, 10 mM EDTA, 20 mg/ml RNase A) supplied. Cells were 
subsequently disrupted by incubating in cell lysis buffer (200 mM NaOH, 1 % 
SDS w/v) for 5 minutes. After neutralization of cell lysate, lysate was loaded 
into purification column. The column was washed by two successive washings. 
Plasmids were finally eluted by NE buffer (5 mM Tris-HCl, pH 8.5) previously 
wanned to 60�C. 
2.4.6 Charging of His-tagged column 
The His-tagged column was first washed with ten volumes of nanopure water. 
Three volumes of 50mM nickel sulphate solution were added, then followed by 
5 volumes of nanopure water and five volumes of equilibration buffer. 
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2.4.7 Washing of His-tagged column 
The His-tagged column was washed with five bed volumes of IM imidazole 
solution, followed by ten bed volumes of nanopure water. The column was 
stored in 20% EtOH at 4°C. 
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Chapter Three. Results 
3.1 UGT1A8 expression in clone 9 and H4IIE after treatment with 
licorice and ISp glycyrrhetinic acid 
Previous studies have shown that licorice was used in formulations to treat and 
relieve pains associated with ulcers and liver diseases. Licorice was shown to 
have therapeutic benefits including anti-inflammatory properties and may 
therefore help relieve the discomforts with arthritic conditions [Kawakami et al, 
2003, Amaryan et al, 2003]. 
ISP glycyrrhetinic acid, one of the active components of licorice, is known for 
its anti-inflammatory properties, which can inhibit the prostaglandins 
metabolizing enzyme [Tsukahara et al, 2005]. It is also known to have 
hepatoprotective properties. However, the mechanism of hepatoprotection is 
still unclear. Therefore, to study the biologic activity of licorice and 18(3 GA in 
the liver would allow us to get a better understanding of the pharmacological 
effects of licorice and its components on the liver. 
In order to study the effect of licorice extract and 18(3 GA on the liver, clone 9 
and H4IIE cell lines were employed to study the cellular responses. The cell 
viability in the presence of licorice was measured to evaluate its potential 
toxicity. Figure 9 shows that the viability of H4IIE decreased with the 
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incubation time. Licorice extract seemed to induce considerable toxic effect 
after twenty hours incubation. The cellular response of clone 9 showed similar 
trend (Figure 10). Both cellular responses appeared to decrease in a 
time-dependent manner. The period of incubation is important in affecting cell 
viability. 
Likewise, 18(3 GA was used to treat H4IIE (Figure 11) and clone 9 (Figure 12) 
to study its effects on the cell lines. Both cell lines responded in a similar 
manner with time. The cell viability decreased in a time-dependent manner. 
To determine the potential toxicity of the licorice extract and 18(3 GA, different 
concentrations of the licorice extract and 18(3 GA were incubated with H4IIE 
and clone 9 cells. Figure 13 showed the viability of H4IIE significantly 
decreased and become level off when the concentration of the licorice extract 
exceeded 0.1 mg/ml. 
Table 2. Summary of IC50 in cell lines 
Licorice extract (mg/ml) 18(3 GA (fiM) 
H4IIE 0.076 50 
Clone 9 0.058 52 
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The IC50 of licorice and 18(3 GA in H4IIE and clone 9 were summarized in table 
2. Figure 14 indicated toxic effect of licorice extract on clone 9 was observed. 
Also, Figure 15 showed the toxic effect of ISp GA on H4IIE after 48 hours of 
incubation while Figure 16 showed the same in clone 9. The results showed that 
18PGA had toxic effects on H4IIE and clone 9. The viability of both cell lines 
decreased significantly when the concentration of 18(3 GA exceeded 5jiM and 
become level off when concentration was greater than 125jiM. As a result, the 
concentration of licorice extract (20mg/kg/day) and ISp GA (160mg/kg/day, 
approximately 60}iM of 18(3 GA based on its molecular weight) were used to 
study their effects on UGT expression. UGTs are one of the important 
detoxifying enzymes in the liver. The activity of UGTl A1 could affect 
detoxification of foreign substances. 
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Figure 9. Time dependent cellular response analyzed with neutral red assay 
of H4IIE cells. H4IIE cells were treated with licorice extract for different 
periods of time up to 120 hours. The data represent the average of five 
independent experiments. (n=3, p<0.05) 
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Figure 10. Time dependent cellular response analyzed with neutral red 
assay of clone 9 cells. Clone 9 cells were treated with licorice extract for 
different periods of time up to 120 hours. The data represent the average of 
five independent experiments. (n=3, p<0.05) 
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Figure 11. Time dependent cellular response analyzed with neutral red 
assay of H4IIE cells. H4IIE cells were treated with 18(3GA for different 
periods of time up to 120 hours. The data represent the average of five 
independent experiments. (rr=3, p<0.05) 
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Figure 12. Time dependent cellular response analyzed with neutral red 
assay of clone 9 cells. Clone 9 cells were treated with 18[3GAfor different 
periods of time up to 120 hours. The data represent the average of five 
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Figure 13. Cellular response of H4IIE cells after 48 hours of licorice 
treatment. The data represent the average of five runs. The viability (%) 
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Figure 14. Cellular response of clone 9 cells after 48 hours of licorice 
treatment. The data represent the average of five runs. The viability (%) 
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Figure 15. Cellular response of H4IIE cells after 48 hours of ISp GA 
treatment. The data represent the average of five runs. The viability (%) 
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Figure 16. Cellular response of clone 9 cells after 48 hours of 18(3 GA 
treatment. The data represent the average of five runs. The viability (%) 
shows the change relative to the control. (n=3, p<0.05) 
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In order to study the effect of treatment process on the expression level of UGT, 
RT-PCR of P-actin as the standard in H4IIE and clone 9 was carried out. Cells 
were treated with licorice extract and ISp GA for different periods of time 
(Figure 17). Essentially, there was no difference on the expression level of 
P-actin among cell lines compared with the control (n=3, p<0.05). In addition, 
longer incubation period did not seem to affect the expression level of P-actin. 
Likewise, the expression level of UGTl A1 in H4IIE and clone 9 was measured 
(Figure 18). There was a slight increase of UGTl Al after treatment of cells for 
48 hours of incubation, while the expression level slightly decreased after 96 
hours of incubation with licorice extract. On the other hand, treatment of cells 
with ISp GA showed a noticeable increase in the expression level after 96 hours 
incubation. By the same approach, the expression of UGTl A7 which showed a 
higher homology with UGT1A8 (Figure 19) and UGT1A8 (Figure 20) were 
measured in H4IIE and clone 9. Figure 19 showed that the expression level of 
UGT1A7 considerably increased after treatment (n二3, p<0.05). 18(3 GA was 
more effective on the induction of UGT1A7 in H4IIE and clone 9. The 
expression level of UGT1A7 after 48 hours was slightly higher than that at 96 
hours. 
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Furthermore, the expression level of UGTl A8 was measured in cells treated 
with licorice extract and ISp GA for 48 hours and 96 hours. Similar trends of 
expression to UGTl A7 were observed. Effects of licorice extract and 18(3 GA 
on UGTl A8 expression was about the same after 48 hours incubation while the 
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Figure 17. RT PGR results of P-actin level in cells after treatment with 
licorice extract and 18(3 GA. RNA was extracted from treated cells and 
cDNA was synthesized with the RNA. (3-actin specific primers were used 
to amplify the specific gene from the cDNA. PGR products were 
visualized with agarose gel with ethidium bromide, (n二3, p<0.05) 
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Figure 18. RT PCR results of UGTlAl level in cells after treatment with 
licorice extract and 18(3 GA. RNA was extracted from treated cells and 
cDNA was synthesized with the RNA. UGTlAl specific primers were 
used to amplify the specific gene from the cDNA. PCR products were 
visualized with agarose gel with ethidium bromide. (n=3, p<0.05) 
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Figure 19. RT PGR results of UGTl A7 level in cells after treatment with 
licorice extract and 18p GA. RNA was extracted from treated cells and 
cDNA was synthesized with the RNA. UGT1A7 specific primers were 
used to amplify the specific gene from the cDNA. PCR products were 




1.6 - p i T 
1.4 -
I 1.2 - T r ^ T 






0 ~——‘~——~^ ~——~‘ ‘ ‘ ‘ ‘ ‘ — ” ‘ 
control H4IIE licorice clone9 licorice H4IIE18yS clone9 18/3 H4IIE licorice clone9 licorice H4I正 18 召 clone9 18/3 
48 hours 48 hours GA 48 hours GA 48 hours 96 hours 96 hours GA 96 hours GA 96 hours 
Figure 20. RT PGR results of UGTl A8 level in cells after treatment with 
licorice extract and 18(3 GA. RNA was extracted from treated cells and 
cDNA was synthesized with the RNA. UGT1A8 specfic primers were used 
to amplify the specific gene from the cDNA. PGR products were 
visualized with agarose gel with ethidium bromide. (rr=3, p<0.05) 
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3.2 UGT1A8 induction in wistar and j/j rats after treatment 
( 
The in vitro study showed positive effects on the expression of UGTs. Thus, 
effects of licorice extract and 18(3 GA on wistar and j/j rats were studied. Wistar 
serves as a wild type while j/j is UGTl A1 deficient. After the treatment, rat 
livers were isolated and RNA was extracted in rat livers (Figure 21) and the 
expressions of genes of interest were evaluated. (3 actin serves as a standard for 
the expression level. Figure 22 shows the expression of p actin in the control 
and rats treated with licorice extract and ISp GA for different periods of time. 
The results indicate that there is no difference in (3 actin expression among the 
control and the treated group [Lee et al, 2004]. 
Figure 23 shows that the level of UGTl A8 was increased after treatment of rats 
with licorice extract and 18(3 GA for different periods of time. The level of 
increment in wistar group was found to be higher than that of the j/j group. The 
induction with ISP GA was stronger than that of licorice. The induction 
processes in the treated rats appeared to increase in a time-dependent manner. 
The results in Figure 24 shows that both licorice and 18[3 GA treatment could 
induce UGT1A8 to a different extent. The level of induction of UGTl A8 after 
treatment with 18|3 GA were higher than that with licorice treatment. The levels 
of induction of UGTl A8 in wistar were higher than that in j/j group [Lee et al, 
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2004]. The results confirmed the expression of UGT1A8 in rats in RT-PCR 
experiment. In relation with the UGT1A8 expression, the expression level of 
UGTlAl in rats was also analyzed. The results (Figure 25) show that there is 
no significant difference in the expression level among the treated group (n=3, 
p<0.05). The treatment process did not seem to affect UGTl A1 induction in 
wistar and j/j rats. 
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Lane 1 and 2: rats in control group 
Lane 3 and 4: rats treated with licorice extract 
Lane 5 and 6: rats treated with ISp GA 
Figure 21. RNA extraction from the Wistar rat livers RNA samples were 
separated under denatured condition with formaldehyde with 1% agarose gel 
under constant voltage (lOOV) for 35 minutes. The gel was stained with 
ethidium bromide. Both 28S and 18S were analyzed in order to check for the 
integrity of the RNA samples. The samples were taken as starting materials for 
RT-PCR and Northern Blot. The results showed good quality of samples prior to 
RT-PCR and Northern Blot analysis. 
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Figure 22. The results of RT-PCR after treatment showed the level of 
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Figure 23. RT-PCR result of UGTlA8 level after reatment. The relative 
unit is defined as the ratio of the intensity of the UGT1A8 band to the 
intensity of the housing keeping gene ((3-actin) (n=3, p<0.05). 
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Figure 24. Northern blot analysis of UGT1A8 mRNA samples after 
treatment of rats for 1 week and 4 weeks. (n=3, p<0.05) 
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Figure 25. Northern blot analysis of UGTl Al after treatment of rats for 1 
week and 4 weeks. The levels of UGTl A1 in the livers were not 
significantly affected (n 二 3, p<0.05). 
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3.3 Construction of pRset-UGTlA8 Vector 
In order to study the biochemical properties of UGT1A8, a sufficient quantity 
of the enzyme needed to be prepared. However, the expression level of the 
enzyme in cell lines is far from sufficiency. Therefore, the enzyme was 
expressed in E.coli expression system. UGT1A8 mRNA was isolated from the 
rat liver and the UGT1A8 coding fragment was amplified and cloned into 
expression vector. E. coli cells were transformed with the expression vector 
followed by IPTG induction to express the protein. Subsequently cells were 
lysed and purified to prepare the target protein. Figure 26 showed the 
amplification of the target gene UGT1A8 in the rat liver. The results indicated 
that a successful amplification of the target gene. Figure 27 showed that the 
presence of the desired construct in the positive clones. The E. coli expression 
system can produce a sufficient amount of protein for the present study. 
Figure 28 indicates the BLAST search result of DNA sequence of the plasmid. 
The results showed there was no mutations in the insert and provided 
confirmative evidence for the plasmid insert sequence. Figure 29 showed 
SDS-PAGE of the expression of the target protein after IPTG induction. Lanes 2 
and 3 indicated the target protein was successfully expressed in 0.5 // M IPTG 
at 37°C for 5 hours. Subsequently, the protein was purified from the cell lysate 
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by centrifugation, followed by chromatography through Ni-column. Figure 30 
showed the protein content of fractions isolated from Ni-column and pellets 
obtained from centrifugation, while Figure 31 showed the activities of purified 
protein towards different substrates were shown. The protein showed activities 
towards 1 -naphthol and coumarin. The activity with 1 -naphthol was higher than 
that of coumarin. On the other hand, phenol red, bilirubin and 4-nitrophenol 
showed no detectable activity with the protein. 
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Figure 26, Amplification of the target gene in the rat liver cDNA pool, the 
expected product size is 1500bp. The DNA sample was cut out and purified for 
ligation with pRset vetor. The bands with the expected size were isolated and 
purified for the cloning expreiment. 
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Figure 27. Restriction digestion of the constructed plasmid. Successful 
digestion with expected product size indicated the presence of the desired 
construct. These positive clones were proceeded to DNA sequencing. 
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I 丨 I I I I 丨丨 I I I 丨 I I I I I M I I 丨 M I I M I M I I I I I I 丨 I I I m 丨 M 丨 I I M 丨 I I I 丨 I I I 
S t o j c t 3 0 1 ACTCAAGAAGTAGGGATGTTTTCTCTACTGAAGCATTCAGGCAAAGGTTTCTTCGAATTA 3 6 0 
Q u e r y 3 6 1 C TGTTTTC AC AC TGTAGAAGTTTGTTTAAGGAC AAGAAGTTAGTGGAGTAC TTGAAGC AG 4 2 0 
I m I m I M m I丨 I M 丨 I 丨 I M 11 M I丨丨 M丨丨丨丨 I M I丨丨 1 1 1 1 1 1 1 1 m M I丨丨 
S b j c t 3 6 1 CTGTTTTCACACTGTAGAAGTTTGTTTAAGGACAAGAAGTTAGTGGAGTACTTGAAGCAG 4 2 0 
Q u e r y 4 2 1 AGTTCGTTTGATGCTGTGTTTCTGGATCCTTTTGATGTGTGTGGCTTAATTCTTGCCAAG 4 8 0 
M 1 1 1 1 1 m 111 m I M l I m M I I I 1 1 M I m 丨 I 丨 I m 1 1 1 1 丨 I 丨 m m m 
S b j c t 4 2 1 AGTTCGTTTGATGCTGTGTTTCTGGATCCTTTTGATGTGTGTGGCTTAATTCTTGCCAAG 4 8 0 
Q u e r y 4已 1 TACTTTTCTCTCCCGTCCGTGGTCTTCAGCGGGGGAJlTATTTTGCCACTJLCCTTGATGAG 5 4 0 
M M I M M I I I 丨 M I M M M 丨 I I m M I M m I 丨丨 I I m 丨 I I 丨丨 M 丨 M I 丨 M M 
S b j c t 4已1 TACTTTTCTCTCCCGTCCGTGGTCTTCAGCGGGGGAATATTTTGCCACTACCTTGATGAG 5 4 0 
Q u e r y 5 4 1 GGTGCCCAGTGCCCCAGTCCTCCTTCTTATGTTCCCAGAATTCTCTCAAAATTCACAGAC 6DD 
M 丨 I I 丨丨丨丨 I I I I I 丨 I M 丨 I I I 丨丨 I I I I M M I I I I M I I M M I I I I M I M I M I I M 
S b j c t 5 4 1 GGTGCCCAGTGCCCCAGTCCTCCTTCTTATGTTCCCAGAATTCTCTCAAAATTCACAGAC 6DD 
Q u e r y 6 0 1 ACCATGACTTTCAAGGAGAGAGTGTGGAACCATCTCTCCTACATGAAGGAGCGTGCATTT 6 6 0 
I I I I I I I 丨 M I I I I I I I I m I I M I I I M m I I I I I I I 丨 I I I I I I I M I I I M I I I I I 
S t o j c t 6 0 1 ACCATGACTTTCAAGGAGAGAGTGTGGAACCATCTCTCCTACATGAAGGAGCGTGCATTT 65D 
Q u e r y 6 6 1 TGCCCCTACTTTTTCAAAACTGCCGTAGAAATTGCCTCTGAAGTTCTCCAGACCCCGGTG 7 2 0 
丨丨 I I M I I M I I I I I I M I I M M I I I I M I 丨 I m I I 丨 m M I M I I I m I M I I I 丨 
S b j c t 6 5 1 TGCCCCTACTTTTTCAAAACTGCCGTAGAAATTGCCTCTGAAGTTCTCCAGACCCCGGTG 720 
Q u e r y 7 2 1 ACTATGAGAGACCTCTTCAGCCCAGTGTCCATTTGGATGTTTCGAACTGACTTTGTGCTG 7已0 
I m 1111111 丨丨 11 m I M I 丨 M 111 丨 I I I M I M I M I 丨 11 丨丨 11 丨 I 丨 I m 丨 I m 
S b j c t 7 2 1 ACTATGAGAGACCTCTTCAGCCCAGTGTCCATTTGGATGTTTCGAACTGACTTTGTGCTG 7 8 0 
Q u e r y 7 B 1 GAGTTCCCCAGACCTGTGATGCCCJUiCATGGTCTACATTG 820 
I I I I I I I I I I I I I I I I 丨 I 丨丨 I I I I I M I I 丨丨 M m M I I 
S b j c t 7曰 1 GAGTTCCCCAGiLCCTGTGATGCCCAACJlTGGTCTACJlTTG 已20 
Figure 28. Blast search of the sequenced target insert. The result showed that 
the submitted sequence was the expected one. Protein expression was 
performed with the clone. 
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3.4 Purification of recombinant UGT1A8 
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Lane 1 ： lysate of non-induced cells 
Lane 2: lysate of 3hrs induced cells (UGTlA8-pRSetB plasmid transformed) 
Lane 3: lysate of 5hrs induced cells (UGTlAS-pRSetB plasmid transformed) 
Lane 4: lysate of induced cells (pRSetB plasmid transformed) 
Lane 5. Benchmark Protein Ladder 
Figure 29. SDS-PAGE showing the expression of the target protein after IPTG 
induction. Bands of about 55kD were observed in lane 2 and 3. The target 
protein in lanes 2 and 3 were successfully expressed under the following 
conditions: 0.5mM IPTG, 37°C, 5 hours. Cell lysates (lOfil) were mixed with 
lOul of 2 X SDS-PAGE Loading Buffer. Samples (20^1) were loaded into the 
well 1 to 4 and the marker (6}il) was loaded into the well 5. The gel was run 
under 125V for 2 hours. The gel was stained with 0.5 % Coomassie Blue for 1 
hours and detained in solution with 10% acetic acid and 30% ethanol. 
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M: Benchmark protein marker 
1: Pellet at 20000 x g 
2: Supernatant at 20000 x g 
3: Fraction 1 
4: Fraction 2 
Figure 30. SDS-PAGE showing the stepwise purification of the target protein. It 
was found that a protein of about 55kDa was collected in fraction 1 using 
Ni-Column eluted with imidazole solution while fraction 2 was found to contain 
no desired protein. 
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3.5 Screening of substrate of the purified enzyme 
coumarin phenol red n ^ CH3 
OH 
I n T I CH2 
bilirubin 
4-ni t rophenol 1-naphthol 
1-naphthol 1.21 土 0.14 
4-nitrophenol ND 
coumarin 0.58 士 0.08 
bilirubin ND 
phenol red ND 
ND: activity not detected 
Figure 31. Different compounds were used for the activity test of the purified 
protein. Values were expressed as nanomoles of substrate converted per 
milligram per minute. Values represent the average of three runs. 
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Chapter Four. Discussion 
4.1 Effects of licorice and 18p glycyrrhetinic acid in the induction of 
UGT1A8 in different cell lines 
The effects of treatments were studied using clone9 and H4IIE. Clone9 was not 
from a cancer origin whereas H4IIE was from a cancerous origin. It is known 
that these two types of cell have very different protein expressing profiles, 
especially those involved in cell division and cell death [Joyce, 2001; Harrison, 
1998]. Although, our target gene did not belong to these two categories, it was 
predicted that the response of cell types to the treatment would be different. It 
was because some drug metabolizing proteins, for example, glutathione 
S-transferase, were found to be up-regulated in tumor cells [Landi, 2000]. 
However, the basal expression of UGTl A8 in tumor cells was similar to that of 
non-cancerous cells. These two types of cells, after the different treatments, also 
responded similarly. Both treatments of licorice extract and 18j3 glycyrrhetinic 
acid were not toxic to the cell lines at low concentration. The IC50 of ISp 
glycyrrhetinic acid in clone 9 and H4IIE were 52|iM and 50jiM, respectively. 
The IC50 of licorice extract in clone9 and H4IIE were 0.058mg/mL and 
0.076mg/mL, respectively. It was suggested that the cells were killed due to the 
change in osmotic pressure. Therefore, the results of cell culture experiment 
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were repeated with a low dose of both extracts and 18(3 glycyrrhetinic acid. 
When the incubation time was kept the same, 18(3 glycyrrhetinic acid showed a 
higher induction effect on UGT1A8 gene expression in both cell types. The 
expression of gene reduced to a lower level after 96 hours of incubation with the 
compound. 
4.2 Comparison of wistar and j/j rats in the induction of UGT1A8 
Two different types of rats were used for the study of the crude extract and one 
single isolated component, 18(3-GA. Both wistar rats and j/j rats were found with 
no change in the morphology of the liver. No nodules or white spots were 
observed. The sizes of the livers were about the same as the control group livers. 
In addition, the P-act in levels were about the same as both the control groups 
and the treatment groups. The level of this gene was found to be up-regulated 
when liver cells were under higher level of division and differentiation after 
liver injury [Ramaekers et al, 2004]. The stable level of (3-actin reflected proper 
control of the treated and the untreated rats. The levels of UGTlAl expression 
were not found to be increased in both types of rats. Both experiments showed 
that the treatment did not induce UGTlAl , which is one of the most constantly-
expressed family members in the liver and it metabolizes a large number of 
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endiobiotics such as, bilirubin. The constant expression of this gene suggested 
that the main drug metabolism pathways remain unchanged [Miners, 2000]. The 
expression level of UGT1A8 was found to be increased in both types of rats 
Lee et al, 2004]. The UGT enzyme of j/j rats with deficiency in UGT genes, 
was considerably reduced [Komaki, 1991]. This heterozygous mutation in the 
genome results in the decreased amount of functional UGTl proteins. The 
induction of UGTl A8 in both types of rat was found to increase by 1.3 to 1.8 
folds. These results suggest that the induction of the gene was regulated at the 
transcriptional level. The treatment of rats can up-regulate the expression level 
of the gene. It can be concluded that both types of rats responded very similarly 
to the treatment. The induction process did not involve the gene product of the 
target gene. It would be helpful to use homozygous Gunn rats to repeat the 
experiment since Gunn rat is a homozygous species. In fact, the project did plan 
to use Gunn rat, however, only a limited number of Gunn rats (only 3) were 
available at the time from the animal centre. The preliminary data showed some 
effects with variations in the rats. It would be better to use rats of the same age 
and sex in order to eliminate the undesirable factors that could affect the 
experiment. 
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4.3 Comparison of licorice and 18(3 glycyrrhetinic acid in the induction 
ofUGTlA8 in rats 
In the experiment, licorice and 18p glycyrrhetinic acid were administered to rats 
for one or four weeks. It was shown that the treatments could up-regulate 
UGT1A8 at a different level. With the same period of treatment duration, 18|3 
glycyrrhetinic acid induced a higher level of the gene when compared to licorice. 
It is suggested that the inductive effect by licorice extract was similar to that of 
18(3 glycyrrhetinic acid. With a longer period of treatment, the level of induction 
was increased. The up-regulation did not reach the maxima yet at the time point. 
It would be worthy to study a longer time course of the treatment. Herbalists 
suggest that herbs should be taken at a low dose for a long period of time in 
order to achieve better protection effects. A longer time course study was useful 
in the study of the long term effects and toxicity of the active components. 
4.4 Comparison of in vivo and in vitro study of drug treatment 
The in vitro results were different from that in the in vivo study. The induction 
level increased to a different extent with time. This can be explained by the 
feed-back control mechanism of any enzyme induction process. The enzyme 
induction is a well-controlled process in which the gene would go up to a 
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maximum level and then drop back to the basal level. Prolonged induction of a 
certain gene would result in loss of equilibrium state of the cell, which may 
result in inhibition of normal metabolism. In the in vivo study, the absorption 
rate and the metabolism of drugs in the GI tract greatly affect the amount of 
drugs reaching the liver. Although the same concentrations of the extract and 
ISp GA were administered following the same treatment procedures to rats, the 
results were quite different, and the expression of UGTl A1 was different from 
UGT1A8 due probably to regulation of different promoters in the expression. 
4.5 Expression of U G T l A7 after drug treatment in vitro 
Rat UGT1A7 has been shown to be closely related to UGT1A8 both in the 
amino acid sequence and the promoter sequence [Gong et al , 2001]. Therefore, 
its level of expression after treatment was also studied with the cell model. It 
was found that UGT1A7 was also up-regulated. The level of induction of this 
gene was even higher than that of UGT1A8. The substrates of UGT1A7 are 
mainly polyphenols. Both isozymes could share substrate specificity. 
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4.6 Protein expression and purification 
Rat liver UGT1A8 was successfully cloned into pRset vector and protein was 
successfully expressed in the host E. coli JM109. The protein was purified with 
IMAC with the yield of 8.5mg per litre of E. coli. and the protein was found in 
the soluble fraction of the bacterial lysate. It was interesting to see that the 
activity of the protein remained about the same when the purification of the 
protein was done at room temperature. The His-tag linked protein did not alter 
the activity of the protein. The purification could be improved by using a 
commercially available chemical-coupling matrix to which the substrate could 
be coupled. The column would provide a platform for more efficient 
purification of the protein. 
4.7 Substrate of UGTl A8 
Our results suggest that compounds sharing similar structure with simple 
aromatic substituents such as 1 -naphthol or coumarin could be substrates of 
UGT1A8. The two compounds differ in their functional groups. The functional 
group of 1 -naphthol is a hydroxyl group whereas that of a couramin is a keto 
group. It was suggested that the protein interacts more strongly with a hydroxyl 
group than a keto one. Bilirubin and phenol red with different structures could 
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not glucuronidated by the enzyme. Phenol red molecule is hydrophilic whereas 
bilirubin is hydrophobic. Both compounds are non-planar molecules. It can be 
concluded that UGT1A8 did not glucuronidate molecules with non-planar 
structure, regardless of its polarity. 4-nitrophenol is basically planar in structure, 
which is similar to 1 -naphthol and coumarin. However, it interacts poorly with 
the protein, probably due to steric effects. In a recently published paper [Webb 
et al, 2005], a number of possible substrates of UGT1A8 were reported (Figure 
32). The result was compared with that of UGT1A7. The two proteins exhibited 
overlapping substrate specificities, but the scope of substrate of UGT1A7 was 
broader. The present study showed 1 -naphthol-like structure was the target 
substrate of the protein. 
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Figure 32. Chemicals that UGT1A8 show high rates of glucuronidation. 1-naphthol 
is the common basic structure. [Webb et al, 2005] 
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Chapter five. Conclusion 
The present study showed that the expression of UGT1A8 could be induced with 
licorice and ISp GA. The induction was more effective with the active component of 
licorice, ISP glycyrrhetinic acid. In both in vivo and in vitro studies, the gene was 
up-regulated after treatment. The treatment did not affect the constantly-expressed 
member of the family, UGTlAl but specifically induced the target gene UGT1A8. 
The response was time and dose dependent. Generally, the responses of wistar rat 
were slightly greater than that of UGT deficient j/j rats. 
In the cell model study, both cancerous cells and non-cancerous cells were used. The 
cells responded similarly. Clone 9 cells showed a more sensitive response to the 
treatment. Induction of UGT1A8 in H4IIE cells was not as high as that in clone 9 
cells. The low basal level and induction response in H4IIE suggest that UGT1A8 
was not an important factor associated with the cellular response that we measured. 
Quantitative amount of protein could be expressed in bacterial host JM109 and 
purified with IMAC. The protein was found in the soluble fraction with biological 
activity. It was the first time that rat UGT1A8 was expressed with the bacterial 
expression system. The low cost and efficient way of expressing UGTl A8 enabled 
us to prepare a sufficient amount of protein for the characterization study. 
In the substrate study，it was found that the protein would convert planar molecules 
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with single hydroxyl group. These findings were consistent with studies on the other 
isoenzymes. The rate of UGT1A8 activity was within the same order of magnitude 
with other studies [Webb et al, 2005]. The chemistry of 1-naphthol provides 
structural information on the substrate specificity of UGT1A8. 
The study of the structure-function relationship would be necessary to get a better 
understanding of this newly identified protein. Site-directed mutagenesis could 
provide useful information on the functional roles of amino acid residues in the 
structure-function relationship. The mechanism of induction could provide insights 
into the properties and modulation of the expression of UGT enzymes. 
Further directions of study of rat UGT1A8 
At this stage, the substrates of rat UGT1A8 tested were synthetic compounds. There 
could be some natural substrates that the protein would glucuronidate, for example 
flavones. As the basal expression level of the protein is low, it is believed that the 
range of substrates of the protein could be narrow. The natural substrate(s) of the 
protein could be found in plants. Phytoalexins are candidates that are worth a trial, 
especially those that shares structural similarities with 1-naphthol. 
Structure-function relationship is important in the study of enzyme function. As the 
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structure of UGT family members remains unclear, study of the structure of 
UGT1A8 could provide useful information on the enzyme. Preliminary study with 
circular dichroism, and protein denaturation could be used to study this enzyme. 
Site-directed mutagenesis could enable us to identify the structurally important 
amino acid residues. 
The expression of a mammalian protein in E. coli is a convenient way of preparing 
the protein. However, the recombinant expression usually results in a reduction in 
the activity and change in properties of the protein. The results should be tested in a 
mammalian expression system since mammalian system can provide more valid 
results on the functions of the protein. Non-liver tissue such as HeLa cell expression 
system is suitable. The functional study of the transformed cell line can provide 
information on the function of the enzyme. 
The induction mechanism for the enzyme remains unclear. It has been known that 
the promoter region shares high homology with that of UGTl A7 [Webb et al, 2005]. 
However, the spectra of substrates of the two isoforms are different. It would be 
interesting to clone the two promoter regions into expression detection systems to 
study the range of chemicals that can trigger promoter activities and to differentiate 
the two promoter regions. A luciferase promoter detection system can be used for 
this study. After cloning of the promoter region at the front of the luciferase gene, the 
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vector could be transfected to cell line. With treatment of different candidates of 
inducer, the level of gene promoter activity could be determined from the luciferase 
activity. 
Possible improvements of the experiment 
In the induction in rats, a homozygous recessive control (Gunn rat) should be used to 
provide a better control. It would be worthwhile to repeat the treatment with different 
dosages and time. The number of rats used could also be increased in order to reduce 
individual differences. In both in vivo and in vitro experiment, some more parameters 
like the inductions of any phase I enzyme could also be investigated. It would 
provide a clearer picture of the effect of the treatment process. 
In the enzyme assay, the activity would be determined by the specific substrate 
concentration. It is inconvenient when a larger number of substrates were required to 
be tested. This process could be improved by measuring the common co-factor, 
UDPGA with HPLC. The results would be more precise for comparison among 
different substrates. 
Although it has been suggested that His-tag has minimal level of the effect towards 
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Appendix Alignment of rat UGT1A8 and human rat UGT1A8 
CLUSTAL W (1.82) multiple sequence alignment 
ugtlal MSWCRSSCSLLLLPCLLLCVLGPSASHAGKLLVIPIDGSHWLSMLGVIQQLQQKGHEW 60 
ugtla8 ---MAPSGCPPSLPLCVCLFLAS-GFAQAGRLLWPMDGSHWFIIQMIVEKLSHRGHEW 56 
ugt 1 a6 ----MAaLPAARLPAGFLFLVLWGSVLGDKLL_DGSHWLSMKEIVEHLSERGHDIV 56 
ugtlaV ----MACLLPAARLPAGFLFLVLWGSVLGDKLLWPQDGSHWLSMKEIVEHLSERGHDIV 56 
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ugtla8 HYLDEGAQCPSPPSYVPRILSKFmiMTFKERWNHLSYMKERAFCPYFFKTAVEIASEV 234 
ugtla6 SLEHMLGQSPSPVSYVPRFYTKFSDHMTFPQRLANFIANILENYLYHCLYSKYEILASDL 235 
ugtla? SLEHMLGQSPSPVSYVPRFYTKFSDHMTFPQRLANFIANILENYLYHCLYSKYEILASDL 235 
^^•氺氺；^：氺本* • •本本本 _本•氺 • •氺 • • •氺••• 
ugtlal LQKEVTVKDLLSPASIWL_FVKDYPRPIMPNMVFIGGINCLQKKALSQEFEAYVNAS 299 
ugtla8 LQTPVTMRDLFSPVSIWMFRTOFVLEFPRPVMPNMVYIGGINCHQGKPLSKEFEAYVNAS 294 
ugtla6 LKRDVSLPAmQN-SLWLLRYDFVFEYPRPWWIFIGGTOCKKKGNLSQEFEAYVNAS 294 
UgtlaV LKRDVSLPALHQN-SLWLLRYDFVFEYPRPVMPNMIFIGGTNCKKKGNLSQEFEAYVNAS 294 
* . * . . * * . * . . * * * * ••木朱朱•：):>!：氺來••：!：：!：氺；!；* • * * . 
Ugtlal GEHGIVVFSLGSMVSEIPEKKAMEIAEALGRIPQTVLWRYTGTra>SNLAKNnLVKWLPQ 359 
ugtlaS GEHGIWFSLGSMVSEIPEKKAMEIAEALGRIPQTVLWRYTGTRPSNLAKNTILVKWLPQ 354 
ugtla6 GEHGIWFSLGSMVSEIPEKKAMEIAEALGRIPQTVLWRYTGTRPSNLAKNTILVKWLPQ 354 
UgtlaV GEHGIWFSLGSMVSEIPEKKAMEIAEALGRIPQTVLWRYTGTIRPSNLAKNTILVKWLPQ 354 
Ugtlal NDLLGHPKARAFmSGSHGIYEGICNGVPMVMMPLFGDQMDNAKRMETRGAGVTUWLE 419 
UgtlaS NDLLGHPKARAFIIBSGSHGIYEGICNGVPMVMMPLFGDQMDNAKRMETRGAGVILNVLE 414 
ugtla6 NDLLGHPKARAFIlHSGSHGIYEGICNGVPMVMMPLFGDQMDNAKMETRGAGVnMLE 414 
ugtla? NDLLGHPKARAFITHSGSHGIYEGICNGVPMVMMPLFGDQMDNAKRMETRGAGVmWLE 414 
Ugtlal _DLENAIJCrVINNKSYKENIMELSSLHKDRPIEPLDLAVFWVEYVMRHKGAPHLRPA 479 
1 0 5 
ugt laS MTADDLENALKTVINNKSYKENIMRLSSLHKDRPIEPLDLAVFWVEYVMRHKGAPHLRPA 474 
ugt la6 MTADDLENAUCIVINNKSYKENIMRLSSLHKDRPIEPLDLAVFWVEYVMRHKGAPHLRPA 474 
ugtlaV MTADDLENALmiNNKSYKENIMRLSSLHKDRPIEPLDLAVFWVEYVMRHKGAPHLRPA 474 
u g t l a l AHDLTWYQYHSLDVIGFLLAIVLTWFIVYKSCAYGCRKCFGGKGRVKKSHKSKIB 535 
UgtlaS AHDLTWQYHSLDVIGFLLAIVLTWFIVYKSCAYGCRKCFGGKGRVKKSHKSfCffl 530 
ugt la6 AHDLTWYQYHSLDVIGFLLAIVLTWFIVYKSCAYGCRKCFGGKGRVKKSHKSKTH 530 
UgtlaV AIDLTWYQYHSUMGFLUIVLTWFIVYKSCAYGCRKCFGGKGRVKKSHKS™ 530 
CLUSTAL W (1.82) mul t ip le sequence alignment 
human.ugtlaS MARTWTSPIPLCVSLLLTGGPAEAGKLLWPMDGaiWFTiqSVVEKLILRGHEVWVMP 60 
r a t_ug t l a8 MAPSGCPPSLPLCVCLFLASGFAQAGRLLWPMDGSHWFUQMIVEKLSHRGHEVWVIP 60 
* * - * •本氺氺冰 *•氺• 氺•氺本本氺氺氺氺it：；!：氺氺氺氺本:(：.：!：*** 本氺氺氺本：^：•冰 
hunian_ugtla8 EVSMXGKSLICIVKTYS 丁 SYTLEDLDEEFMDPAM(^ WKA(^ VRSIJSLFLSSSNGFFNLP 120 
ra t_ug t l a8 EVSWHMGKSLNFrVKTYSVSYTLEDLN™CFF_WKTQEVGMFSLLKHSGKGFFELL 120 
human_ugtla8 FSHCRSLF^ ^RKLVEYLKESSFDAVFLDPFDACGLIVAKYFSLPSWFARGIACHYLEEG 180 
ra t_ug t l a8 FSHCRSLFKDKKLVEYLKQSSFDAWLDPFDVCGLILAKYFSLPSWFSGGIFCHYLDEG 180 
：！：：):；!；本本本本：)：.：(：.本；！：；！：！！：本：！：水.宋块本：)：：!：：!；；!：*氺*木 * * * * 氺;)；.*!(; 
human_ugtla8 AQCPAPLSYVPRILLGFSDAMTFKERVRNHIMHLEEHLFOQYFSKNALEIASEILQTPVT 240 
ra t_ug t la8 AQCPSPPSYVPRILSKFmMTFKERWNHLSYMKERAFCPYFFmVEIASEVLQTPVT 240 
氺本本氺_氺氺氺氺求;t：水本 •本.氺本氺氺本宋：)；术本• •• •氺• (氺本本 * 本•氺本本氺氺• 氺氺本氺 
hunian_ugtla8 AYDLYSHTSIWLLRTOFVLDYPKPVMPNMIFIGGINCHQGKPLPMEFEAYINASGEHGIV 300 
ra t_ugt la8 MI^ LFSPVSIWMFRTOFVLEFPRPWNMVYIGGINCHQGKPLSKEFEAYVNASGEHGIV 300 
本华•氺 氺氺氺.•氺氺氺氺本本丨•氺氺本;fc氺氺• • 氺氺本氺伞本氺氺氺;i：* ：！：:}：;^：*;^ _氺氺氺^！：；！；氺氺氺氺 
human_ugtla8 VFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGH 360 
ra t_ugt la8 VFSLGSMVSEIPEKKAMEIAEALGRIPQTVLWRYTGTl^ SNLAKNTILVKWLPQNDLLGH 360 
氺本:jc氺氺:};氺氺氺氺木氺氺本氺：；；木；}：氺•本宋氺•氺氺氺氺;i：*：!：木氺;1：氺氺;i：氺*本：}：本*；|:氺氺氺氺*氺本氺本;氺氺 
human—ugt 1 a8 PMmFimGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVILNVLEMTSEDL 420 
ra t_ugt la8 PKARAFITHSGSHGIYEGICNGVPMVMMPLFGDQMDNAKRMET^ GAGVILNVLEMTADDL 420 
* •氺本氺•氺氺氺氺•傘氺氺氺:i：；；：伞本本：}：；}：水氺木氺*氺氺氺木:ic本氺:j：氺氺*丨：}：氺氺氺氺氺氺本本氺水* •  ••本氺 
human_ugt1a8 ENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTW 480 
rat_ugtla8 ENALKTVINNKSYKENIMRLSSLHKDRPIEPLDLAVFWVEYVMRHKGAPHLRPAAHDLTW 480 
；！：木块：}:：!： •:):；!!>(: •本木木*水:)：!|:氺;宋：；！；！：：；：本本•木牟本:！：糸：；：华宋泳本*** 
human_ugtla8 YQYHSLDVIGFLLAWLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKIH 530 
ra t_ugt la8 YQYHSIDVIGFLLAIVLTWFIVYKSCAYGCRKCFGGKGRVKKSHKSm 530 
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